Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

about

GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases.Glutathione S -transferase π: a potential role in antitumor therapy

P2860

Q28275543-9706BA63-56F6-4531-95D8-432B647199EC Q48181201-7D2E4213-BF6F-4CB1-B168-AD6D7142FE4C Q58694500-84E68339-9904-4EF6-A1AB-4F8A271EC02A

P2860

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

Item

http://www.wikidata.org/entity/Q38365967

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

@en

type

Item

label

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

@en

prefLabel

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

@en

P1476

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

@en

P2093

Daruka Mahadevan

http://www.w3.org/2001/XMLSchema#string

Gregory Ryan Sutton

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of JNK signaling by GSTp

New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice

Epidemiology of myelodysplastic syndromes

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis

Efficacy of lenalidomide in myelodysplastic syndromes.

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

P304

725-733

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2015.1021003

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25724698

http://www.w3.org/2001/XMLSchema#string

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

about

P2860

P2860

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698